The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia
Abstract
OBJECTIVE: The development of both type I and type II diabetes after initiation of some atypical neuroleptics has been reported, primarily in studies involving small series of patients. This study used administrative data from a large national sample of patients with a diagnosis of schizophrenia to compare the prevalence of diabetes mellitus in patients receiving prescriptions for atypical and typical neuroleptics. METHOD: All outpatients with schizophrenia treated with typical and atypical neuroleptics over 4 months in 1999 in the Veterans Health Administration of the Department of Veterans Affairs (VA) were included in this study. Patients treated with atypical neuroleptics were those who received prescriptions for clozapine, olanzapine, risperidone, or quetiapine. Patients with a diagnosis of diabetes were also identified by using ICD-9 codes in VA administrative databases. The prevalence of diabetes mellitus across age groups and among patients receiving prescriptions for different atypical neuroleptics was examined with multiple logistic regression. RESULTS: A total of 38,632 patients were included in the study: 15,984 (41.4%) received typical neuroleptics and 22,648 (58.6%) received any atypical neuroleptic (1,207 [5.3%] received clozapine; 10,970 [48.4%], olanzapine; 955 [4.2%], quetiapine; and 9,903 [43.7%], risperidone; 387 patients received prescriptions for more than one atypical neuroleptic). When the effects of age were controlled, patients who received atypical neuroleptics were 9% more likely to have diabetes than those who received typical neuroleptics, and the prevalence of diabetes was significantly increased for patients who received clozapine, olanzapine, and quetiapine, but not risperidone. However, for patients less than 40 years old, all of the atypical neuroleptics were associated with a significantly increased prevalence of diabetes. CONCLUSIONS: In this large group of patients with schizophrenia, receipt of a prescription for atypical neuroleptics was significantly associated with diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
Prevalence and Correlates of Diabetes in National Schizophrenia Samples
Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., & Lehman, A. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033504 · Cited by 569
Quetiapine in Patients With Schizophrenia: A High- and Low-Dose Double-blind Comparison With Placebo
Small, J. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180067009 · Cited by 478
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
Cited by
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Clinical Practice Recommendations
Fowler, M. J. (2011) · Clinical Diabetes · doi:10.2337/diaclin.29.4.163 · Cited by 995
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment
Musselman, D. L., Betan, E., Larsen, H., & Phillips, L. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00569-9 · Cited by 671
Medical Comorbidity in Schizophrenia
Jeste, D. V., Gladsjo, J. A., Lindamer, L. A., & Lacro, J. P. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.3.413 · Cited by 624
Freedman, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035458 · Cited by 587
Integrating Physical Activity Into Mental Health Services for Persons With Serious Mental Illness
Richardson, C. R., Faulkner, G., McDevitt, J., Skrinar, G. S., Hutchinson, D. S., & Piette, J. D. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.3.324 · Cited by 493
OECD (2021) · OECD Health Policy Studies · doi:10.1787/4ed890f6-en · Cited by 407
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Management of behavioral problems in Alzheimer's disease
Gauthier, S., Cummings, J., Ballard, C., Brodaty, H., Grossberg, G., Robert, P., & Lyketsos, C. (2010) · International Psychogeriatrics · doi:10.1017/s1041610209991505 · Cited by 361
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 356
Zimmermann, U., Kraus, T., Himmerich, H., Schuld, A., & Pollmächer, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00018-9 · Cited by 347
Suppes, T., Dennehy, E. B., Hirschfeld, R. M. A., Altshuler, L. L., Bowden, C. L., Calabrese, J. R., Crismon, M. L., Ketter, T. A., Sachs, G. S., Swann, A. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0710 · Cited by 330
Rosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Self-citationHenderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P., Evins, A. E., Hayden, D., Weber, M. T., Anderson, E. J., Allison, D. B., Daley, T. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.19 · Cited by 319
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315
Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus
Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071065 · Cited by 314
Sikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., & Lieberman, J. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300327 · Cited by 308
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part II
PAPPADOPULOS, E., MACINTYRE, J. C., CRISMON, M. L., FINDLING, R. L., MALONE, R. P., DERIVAN, A., SCHOOLER, N., SIKICH, L., GREENHILL, L., SCHUR, S. B., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200302000-00008 · Cited by 289
Smith, M., Hopkins, D., Peveler, R. C., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 275
Pharmacological Agents That Directly Modulate Insulin Secretion
Doyle, M. E., & Egan, J. M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.7 · Cited by 256
Bobes, J., Arango, C., Garcia-Garcia, M., & Rejas, J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1030 · Cited by 181
“Apart from increased suicidal tendencies and other possible reasons such as increased risk for cardiovascular and/or endocrine disorders, lifestyle factors appears as potential contributors to poor outcomes in such patients (Sernyak et al., 2002; Bobes et al., 2003; Wirshing, 2004; Enger et al., 2004; Lamberti et al.,…”
InfluentialMeaney, A. M., & O'Keane, V. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.013 · Cited by 92
Cardiovascular aspects of antipsychotics
Raedler, T. J. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833f46c9 · Cited by 89
Antipsychotics and diabetes: review of non-prospective data
Haddad, P. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s80 · Cited by 71
“Pharmaco-epidemiological studies can be cross-sectional in design and determine prevalence rates of diabetes (e.g. Sernyak et al, 2002), but most assess the risk of new cases of diabetes appearing during a specified observation period – i.e. they assess incidence rates.”
BackgroundResultRisk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Citrome, L. L., Holt, R. I., Zachry, W. M., Clewell, J. D., Orth, P. A., Karagianis, J. L., & Hoffmann, V. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k141 · Cited by 64
Nuevo, R., Chatterji, S., Fraguas, D., Verdes, E., Naidoo, N., Arango, C., & Ayuso-Mateos, J. L. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06801 · Cited by 48
The unchanging mortality gap for people with schizophrenia.
Chwastiak, L. A., & Tek, C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61072-2 · Cited by 41
Dregan, A., McNeill, A., Gaughran, F., Jones, P. B., Bazley, A., Cross, S., Lillywhite, K., Armstrong, D., Smith, S., Osborn, D. P. J., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230674 · Cited by 41
Chue, P., & Kovacs, C. S. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00063.x · Cited by 32
Rao (2008) · doi:10.1016/j.pnpbp.2008.05.013 · Cited by 32
Jerrell, J., McIntyre, R., & Tripathi, A. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.3.2 · Cited by 31
Sumiyoshi, T., Roy, A., Anil, A. E., Jayathilake, K., Ertugrul, A., & Meltzer, H. Y. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000126668.67820.00 · Cited by 28
Diabetic retinopathy screening in persons with mental illness: a literature review
Bradley, E. R., & Delaffon, V. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000437 · Cited by 22
“6 The additional risk of diabetes posed by antipsychotic treatment, in particular second generation antipsychotics, is widely acknowledged 7–9 ; olanzapine 10 and clozapine 11 carrying particular risks.”
Metadata
- Authors
- Sernyak, M. J., Leslie, D. L., Alarcon, R. D., Losonczy, M. F., & Rosenheck, R.
- Venue
- American Journal of Psychiatry
- Published
- 2002-04-01
- Volume
- 159
- Issue
- 4
- Pages
- 561-566
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2131537784
- Cited by
- 623
- References
- 27
- FWCI
- 45.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.